Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Heartseed, Inc. ( (JP:219A) ) has shared an announcement.
Heartseed, Inc. announced the completion of a 30-day review by the Pharmaceuticals and Medical Devices Agency for their clinical trial notification of the HS-005 therapy, allowing the trial to commence. The EMERALD study will evaluate the safety and efficacy of this therapy in treating severe heart failure, planning to enroll 14 patients. The company plans to start patient administration in 2026, with no changes to their current earnings forecast.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen1361.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed, Inc. operates in the biotechnology industry, focusing on developing advanced therapies for heart conditions. Their primary product includes cardiac remuscularization therapy using allogeneic iPS cell-derived cardiomyocyte spheroids, targeting severe heart failure due to ischemic heart disease and dilated cardiomyopathy.
Average Trading Volume: 1,547,045
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen39.53B
For a thorough assessment of 219A stock, go to TipRanks’ Stock Analysis page.